Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

AnPac Bio-Medical Science

Nasdaq:ANPC
Snowflake Description

Limited growth with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ANPC
Nasdaq
$90M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Anpac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People’s Republic of China and the United States. The last earnings update was 150 days ago. More info.


Add to Portfolio Compare Print
ANPC Share Price and Events
7 Day Returns
-
NasdaqGM:ANPC
4.7%
US Biotechs
9.9%
US Market
1 Year Returns
-
NasdaqGM:ANPC
-0.4%
US Biotechs
-11.9%
US Market
ANPC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AnPac Bio-Medical Science (ANPC) - -5.9% - - - -
US Biotechs 4.7% -6.7% -8.6% -0.4% 6.6% -10.6%
US Market 9.9% -15% -21.5% -11.9% 5.1% 18.1%
1 Year Return vs Industry and Market
  • No trading data on ANPC.
  • No trading data on ANPC.
Price Volatility
Industry
5yr Volatility vs Market

ANPC Value

 Is AnPac Bio-Medical Science undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether AnPac Bio-Medical Science is trading at an attractive price based on the cash flow it is expected to produce in the future. But as AnPac Bio-Medical Science has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for AnPac Bio-Medical Science. This is due to cash flow or dividend data being unavailable. The share price is $8.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AnPac Bio-Medical Science's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AnPac Bio-Medical Science's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:ANPC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in CNY CN¥-7.92
NasdaqGM:ANPC Share Price ** NasdaqGM (2020-03-27) in USD $8
NasdaqGM:ANPC Share Price converted to CNY reporting currency Exchange rate (USD/ CNY) 7.096 CN¥56.77
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,945 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AnPac Bio-Medical Science.

NasdaqGM:ANPC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ANPC Share Price ÷ EPS (both in CNY)

= 56.77 ÷ -7.92

-7.17x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AnPac Bio-Medical Science is loss making, we can't compare its value to the US Biotechs industry average.
  • AnPac Bio-Medical Science is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does AnPac Bio-Medical Science's expected growth come at a high price?
Raw Data
NasdaqGM:ANPC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.17x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-3.2%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,007 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for AnPac Bio-Medical Science, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on AnPac Bio-Medical Science's assets?
Raw Data
NasdaqGM:ANPC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in CNY CN¥-5.31
NasdaqGM:ANPC Share Price * NasdaqGM (2020-03-27) in USD $8
NasdaqGM:ANPC Share Price converted to CNY reporting currency Exchange rate (USD/ CNY) 7.096 CN¥56.77
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,156 Publicly-Listed Companies 1.26x
NasdaqGM:ANPC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ANPC Share Price ÷ Book Value per Share (both in CNY)

= 56.77 ÷ -5.31

-10.69x

* Primary Listing of AnPac Bio-Medical Science.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AnPac Bio-Medical Science has negative assets, we can't compare the value of its assets to the US Biotechs industry average.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through AnPac Bio-Medical Science's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Biotechs industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess AnPac Bio-Medical Science's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. AnPac Bio-Medical Science has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ANPC Future Performance

 How is AnPac Bio-Medical Science expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-3.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is AnPac Bio-Medical Science expected to grow at an attractive rate?
  • Unable to compare AnPac Bio-Medical Science's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare AnPac Bio-Medical Science's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • AnPac Bio-Medical Science's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:ANPC Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:ANPC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -3.2%
NasdaqGM:ANPC Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 92.6%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.5%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:ANPC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:ANPC Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 71 -12 -79 1
2020-12-31 14 16 -97 1
2020-03-29
2019-12-31 11 -4 -90 1
NasdaqGM:ANPC Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2019-09-30 12 -41 -69
2018-12-31 10 -31 -42
2017-12-31 6 -22 -39

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • AnPac Bio-Medical Science is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • AnPac Bio-Medical Science's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:ANPC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from AnPac Bio-Medical Science Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ANPC Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -7.23 -7.23 -7.23 1.00
2020-12-31 -9.78 -9.78 -9.78 1.00
2020-03-29
2019-12-31 -9.86 -9.86 -9.86 1.00
NasdaqGM:ANPC Past Financials Data
Date (Data in CNY Millions) EPS *
2019-09-30 -7.92
2018-12-31 -4.93
2017-12-31 -4.92

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if AnPac Bio-Medical Science will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess AnPac Bio-Medical Science's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AnPac Bio-Medical Science has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ANPC Past Performance

  How has AnPac Bio-Medical Science performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AnPac Bio-Medical Science's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AnPac Bio-Medical Science does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare AnPac Bio-Medical Science's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare AnPac Bio-Medical Science's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
AnPac Bio-Medical Science's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AnPac Bio-Medical Science Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ANPC Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 11.73 -68.60 63.87 9.50
2018-12-31 10.25 -42.06 38.67 10.11
2017-12-31 5.69 -39.08 31.43 11.41

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if AnPac Bio-Medical Science has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if AnPac Bio-Medical Science has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if AnPac Bio-Medical Science improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess AnPac Bio-Medical Science's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AnPac Bio-Medical Science has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ANPC Health

 How is AnPac Bio-Medical Science's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AnPac Bio-Medical Science's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AnPac Bio-Medical Science's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • AnPac Bio-Medical Science's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of AnPac Bio-Medical Science's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • AnPac Bio-Medical Science has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AnPac Bio-Medical Science Company Filings, last reported 5 months ago.

NasdaqGM:ANPC Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 -39.96 57.31 23.98
2018-12-31 -22.39 53.82 12.89
2017-12-31 9.50 15.58 11.41
  • AnPac Bio-Medical Science has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if AnPac Bio-Medical Science's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • AnPac Bio-Medical Science has less than a year of cash runway based on current free cash flow.
  • AnPac Bio-Medical Science has less than a year of cash runway if free cash flow continues to grow at historical rates of 25.4% each year.
X
Financial health checks
We assess AnPac Bio-Medical Science's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AnPac Bio-Medical Science has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ANPC Dividends

 What is AnPac Bio-Medical Science's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from AnPac Bio-Medical Science dividends.
If you bought $2,000 of AnPac Bio-Medical Science shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate AnPac Bio-Medical Science's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate AnPac Bio-Medical Science's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:ANPC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 66 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1946 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:ANPC Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2020-03-29
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as AnPac Bio-Medical Science has not reported any payouts.
  • Unable to verify if AnPac Bio-Medical Science's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of AnPac Bio-Medical Science's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as AnPac Bio-Medical Science has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess AnPac Bio-Medical Science's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AnPac Bio-Medical Science afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AnPac Bio-Medical Science has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ANPC Management

 What is the CEO of AnPac Bio-Medical Science's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Chang Yu
AGE 60
TENURE AS CEO 10.2 years
CEO Bio

Dr. Chris Chang Yu founded Anpac Bio-Medical Science Co., Ltd. in 2008 and has been as its Cchairman of the Board of Directors and Chief Executive Officer since January 2010. Over 20 years, Dr. Yu's work has spanned the fields of medical devices for cancer screening, biology (bio-membranes), signal detection, transducer design and fabrications, reagents, IC materials and integrated circuits. Dr. Yu also worked at three U. S. Fortune 500 companies, including serving as a group leader in the research and development division at Rockwell Co., Ltd. from 1994 to 1995, engineer at Motorola Co., Ltd. from 1992 to 1994, and senior engineer at Micron Technology Co., Ltd. from 1989 to 1992. As a R&D manager and later as R&D director, he played a critical role in building a small division of a NYSE company into a highly successful high tech company with more than $200 million in revenue and IPO on NSDAQ. He is an inventor of more than 200 patent applications with close to 100 patents issued. He attended medical school. Dr. Yu received his bachelor and master’s degrees in physics from the University of Missouri Kansus-City Campus in 1983 and 1984, respectively. He received his doctoral degree in physics from the Pennsylvania State University in 1990.

CEO Compensation
  • Insufficient data for Chris Chang to compare compensation growth.
  • Insufficient data for Chris Chang to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the AnPac Bio-Medical Science management team in years:

7.5
Average Tenure
59
Average Age
  • The average tenure for the AnPac Bio-Medical Science management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Chris Chang Yu

TITLE
Co-Founder
AGE
60
TENURE
10.2 yrs

Herbert Yu

TITLE
Co-Founder & Chief Medical Officer
AGE
62
TENURE
12.2 yrs

Rain Yu Zhang

TITLE
Chief Financial Officer
AGE
41
TENURE
1 yrs

Weidong Dai

TITLE
China President
AGE
58
TENURE
4.9 yrs
Board of Directors Tenure

Average tenure and age of the AnPac Bio-Medical Science board of directors in years:

1.6
Average Tenure
50
Average Age
  • The average tenure for the AnPac Bio-Medical Science board of directors is less than 3 years, this suggests a new board.
Board of Directors

Chris Chang Yu

TITLE
Co-Founder
AGE
60
TENURE
10.2 yrs

Xing Pu

TITLE
Independent Director
AGE
50
TENURE
0.5 yrs

Ren Luo

TITLE
Independent Director
AGE
61
TENURE
0.5 yrs

Lee Shulman

TITLE
Member of Technical Advisory Board
TENURE
1.4 yrs

Feng Guo

TITLE
Director
AGE
39
TENURE
1.6 yrs

Jiefeng Gu

TITLE
Director
AGE
35
TENURE
3.9 yrs

Sarah Yu

TITLE
Director
AGE
30
TENURE
1.6 yrs

Lin Yu

TITLE
Director
AGE
61
TENURE
10.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess AnPac Bio-Medical Science's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AnPac Bio-Medical Science has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ANPC News

Simply Wall St News

ANPC Company Info

Description

Anpac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People’s Republic of China and the United States. It also manufactures cancer differentiation analysis devices; and offers physical checkup package services. The company was founded in 2010 and is headquartered in Lishui, the People’s Republic of China.

Details
Name: AnPac Bio-Medical Science Co., Ltd.
ANPC
Exchange: NasdaqGM
Founded: 2010
$89,610,880
11,201,360
Website: http://www.anpacbio.com
Address: AnPac Bio-Medical Science Co., Ltd.
801 Bixing Street,
Bihu County,
Lishui,
Zhejiang Province, 323006,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ANPC SPONSORED ADS Nasdaq Global Market US USD 30. Jan 2020
Number of employees
Current staff
Staff numbers
101
AnPac Bio-Medical Science employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/29 05:22
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/23
Last earnings filing: 2019/10/31
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.